Podcast
Monty Pal
Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
Summary
- The pharmacological response of TDBs involves complex interactions between T-cells, tumor cells, and TDBs, posing challenges in understanding pharmacokinetics, tissue distribution, target engagement, and exposure-response relationships.
- Dosing strategy is crucial for determining the therapeutic window, aiming to maximize efficacy while managing mechanism-related adverse events like cytokine release syndrome and neurological issues, which are most prominent during initial treatment cycles.
- Kinetic characterization of exposure/target engagement and safety/efficacy outcomes is essential for designing optimal dosing regimens to balance the benefit/risk of TDB agents.
- The review covers clinical pharmacological considerations in TDB drug discovery and development, summarizes current clinical developments, and suggests future opportunities for insights through quantitative clinical pharmacology.
Advancements in antibody engineering and recent clinical successes have led to enthusiasm for the development of bispecific modalities with the unique ability to bind to two distinct antigens or two different epitopes on the same antigen. T‐cell directing/engaging bispecific agents (TDBs), in particular, are rapidly becoming an important class of molecules in oncology drug development. These agents enhance recruitment of effector cells (e.g., cytotoxic T‐cells) to tumor‐associated/specific antigens for targeted cell killing. Like other T‐cell engaging therapies, TDBs engage the host’s T‐cells thereby driving deep and durable clinical response beyond treatment termination. However, unlike chimeric antigen receptor T‐cell therapies, which take weeks from collection of patients’ T‐cells to availability of treatment product, TDBs are available off‐the‐shelf.
quantitative clinical pharmacology, T-Cell, TDB, bispecificss
Related Topics
You May Also Like
Monty Pal
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
iNIZIO
Clinical Educator Oncology Program Improves Adherence by 29%
Article
Forbes Books Press Release Official